Quick summary
If you're currently taking oral Wegovy and thinking about switching to Mounjaro, you're not alone.
Mounjaro has become one of the most talked-about weight loss medications available, and some people taking oral Wegovy want to know whether switching could offer a different experience—whether that's due to side effects, results, or simply wanting to try a different option.
The good news is that switching from oral Wegovy to Mounjaro is possible—but it should always be done under the guidance of a clinician.
In this guide, we'll explain how switching from oral Wegovy to Mounjaro works, who might benefit from making the change, and what you can expect once you start treatment.
Can you switch from oral Wegovy to Mounjaro?
Yes. It's possible to switch from oral Wegovy (semaglutide) to Mounjaro (tirzepatide), provided our Clinical Team feels it's appropriate for you.
It's worth understanding upfront that this isn't a like-for-like swap. Mounjaro and oral Wegovy aren't the same medicine, and there is no validated milligram-to-milligram conversion between them. Mounjaro is a dual GIP/GLP-1 receptor agonist given as a weekly injection, while oral Wegovy is a GLP-1 receptor agonist only, taken as a daily tablet. The two also differ in dosing schedule and tolerability profile.¹
Because of this, our Clinical Team doesn't aim to "match" your oral Wegovy dose to an equivalent Mounjaro dose. Instead, the goal is to start you on a Mounjaro dose that's likely to be well tolerated, while preserving as much treatment continuity as possible, based on your current dose, how long you've been established on treatment, and how well you've tolerated it.
Why do people switch from oral Wegovy to Mounjaro?
Everyone's weight loss journey is different, and there are several reasons why someone might consider switching medications.
You're not getting the results you'd hoped for
Oral semaglutide has much lower bioavailability than injectable GLP-1 medications, so some people find their appetite suppression feels weaker than expected, or that weight loss has slowed or plateaued. Mounjaro's dual mechanism means some people respond differently to it.
You'd prefer a weekly injection to a daily tablet
Oral Wegovy needs to be taken every morning on an empty stomach, with a 30-minute wait before eating or drinking anything else. If that routine doesn't suit you, a once-weekly injection may feel more manageable.
You're experiencing side effects
Digestive side effects are common with both medications, particularly while your body is adjusting. These can include:
- Nausea
- Vomiting
- Constipation
- Diarrhoea
- Bloating
- Indigestion
Some people find they tolerate one medication better than another, even though both work on related pathways.
Our Clinical Team recommends a different treatment
Our Clinical Team may suggest switching medications if:
- your response to oral Wegovy has been weaker than expected
- you've experienced troublesome side effects
- another medication may better suit your medical history or routine
- your treatment goals have changed
The decision should always be based on your individual circumstances rather than weight loss alone.
How does the switch work?
Because oral Wegovy and Mounjaro are different medicines, switching between them requires a bit more care than moving between doses of the same medication.
As oral Wegovy is taken daily and has low residual exposure, there's typically no need for an extended gap between your last tablet and your first Mounjaro injection—but our Clinical Team will confirm the exact timing that's right for you, taking into account your current dose and how established you are on treatment.
Never take oral Wegovy and Mounjaro together, and never combine either medication with another GLP-1 or GIP/GLP-1 treatment.
What dose of Mounjaro will I start on?
Since there's no validated dose-equivalence table between oral Wegovy and Mounjaro, your starting dose is based on pragmatic guidance rather than a direct conversion. As a general guide:

If you're on the highest oral dose (25 mg), it's worth knowing that jumping straight to a higher Mounjaro dose, such as 15 mg, isn't something our Clinical Team would do routinely—this would only be considered with strong clinical rationale and a clear history of excellent tolerance. In most cases, 10 mg is the recommended starting point even for well-established, higher-dose patients.
It's jumping to the higher end of the Mounjaro range that needs a more cautious, individualised approach.
How do you take Mounjaro?
Unlike oral Wegovy, which is taken every day, Mounjaro is given once a week by injection, ideally on the same day each week. It's injected subcutaneously (under the skin), typically into the abdomen, thigh or upper arm, with the injection site rotated weekly. Our Clinical Team and the patient information leaflet that comes with your prescription will guide you through the injection technique in detail.
One practical difference many people notice: unlike oral Wegovy, Mounjaro doesn't come with fasting or timing restrictions, so there's no need to plan your morning routine around it.
Will Mounjaro work as well as oral Wegovy?
Mounjaro and oral Wegovy work differently in the body, and they haven't been directly compared in trials using the newly approved oral formulation. Independent clinical studies for each drug have yielded varying mean weight reduction outcomes; specifically, some evidence indicates that Mounjaro (tirzepatide) research demonstrated greater average percentages than those seen in semaglutide studies.² Nevertheless, because these treatments were not evaluated head-to-head within the same study, a direct comparison is not possible, and your own experience may deviate notably from clinical trial means.
That said, average results don't tell the whole story. Many factors influence how much weight you lose, including your starting weight, nutrition, physical activity, how consistently you take your medication, and your individual response to treatment. Some people who've had a limited response to oral semaglutide find Mounjaro's dual mechanism works well for them—but this varies from person to person.
What should you expect after switching?
The first few weeks after switching often feel similar to when you first started a GLP-1 medication, since Mounjaro works on a different combination of receptors to oral Wegovy.
You may notice:
- changes in appetite as your body adjusts to the new medication
- possible mild injection-site reactions, such as redness or itching
- mild digestive symptoms while your body adjusts, particularly in the first few weeks
Because Mounjaro is injected weekly rather than taken daily, many people find the change in routine straightforward once the switch is underway.
What side effects can you expect?
The most common side effects of Mounjaro include:
- nausea
- vomiting
- constipation
- diarrhoea
- stomach pain
- bloating
- indigestion
- injection-site reactions, such as redness, itching or bruising
Digestive symptoms are typically manageable and frequently subside as your system adapts to the treatment.¹
Eating smaller meals, staying hydrated and avoiding large, high-fat meals can help reduce digestive symptoms. If your side effects become severe or persistent, you should contact our Clinical Team.
Should you switch?
Whether switching is the right decision depends on your individual circumstances. If you haven't seen the results you'd hoped for on oral Wegovy, you'd prefer a weekly injection to a daily tablet, or our Clinical Team feels Mounjaro is a better fit, switching may be appropriate.
The most important thing is that any change in medication is made under clinical supervision, with a starting dose chosen for you individually, so your treatment can continue safely and effectively.
If you're unsure which medication is right for you, our Clinical Team can help you decide based on your goals, medical history and previous treatment experience.
Wegovy is here! Start your free assessment
Switch from oral Wegovy to Mounjaro safely with Habitual
Mounjaro is here! Start your free assessment
References
[1] Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.
[2] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
[3] Medicines and Healthcare products Regulatory Agency. First GLP-1 tablet for weight loss approved in the UK. Published June 2026.